Skip to Content
Merck
CN
  • Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.

Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society (2010-07-30)
Jan O Aasly, Carles Vilariño-Güell, Justus C Dachsel, Philip J Webber, Andrew B West, Kristoffer Haugarvoll, Krisztina K Johansen, Mathias Toft, John G Nutt, Haydeh Payami, Jennifer M Kachergus, Sarah J Lincoln, Amela Felic, Christian Wider, Alexandra I Soto-Ortolaza, Stephanie A Cobb, Linda R White, Owen A Ross, Matthew J Farrer
ABSTRACT

Genealogical investigation of a large Norwegian family (F04) with autosomal dominant parkinsonism has identified 18 affected family members over four generations. Genetic studies have revealed a novel pathogenic LRRK2 mutation c.4309 A>C (p.Asn1437His) that co-segregates with disease manifestation (LOD = 3.15, θ = 0). Affected carriers have an early age at onset (48 ± 7.7 SD years) and are clinically asymmetric and levodopa responsive. The variant was absent in 623 Norwegian control subjects. Further screening of patients from the same population identified one additional affected carrier (1 of 692) with familial parkinsonism who shares the same haplotype. The mutation is located within the Roc domain of the protein and enhances GTP-binding and kinase activity, further implicating these activities as the mechanisms that underlie LRRK2-linked parkinsonism.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-c-Myc antibody, Mouse monoclonal, clone 9E10, purified from hybridoma cell culture